Can you sum up the aim of this project in 10 words?
To determine whether lignocaine is an effective and safe alternative analgesic agent compared to conventional opioid therapy in patients with suspected STEMI.
What have you discovered in this area in the past?
That long held notions of first line management in STEMI can be wrong. We recently showed that oxygen in normoxic patients with ACS is not warranted, and given the increasing data highlighting opioids inhibit gut absorption of antiplatelet agents, it is time to test their efficacy in a randomised controlled trial.
What will your research entail?
We will perform a Phase II, multi-centre, randomised controlled non-inferiority trial of lignocaine versus fentanyl in pre-hospital patients with suspected STEMI. The trial will be coordinated by Ambulance Victoria Research Division and Monash University.
What aspect of this research excites you the most?
For over 50 years every ambulance and ED have been administering opioids to patients with ischaemic chest pain, without significant evidence of benefit. This trial will shed light on if this remains best practice.
How long before this work might impact patient care?
Whilst acknowledging this is a relatively small phase 2 study, similarly to our trial of oxygen in STEMI, results of the trial have the potential to rapidly change our approach to ischemic chest pain.